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n nonneuronal cells, the cell surface protein dystroglycan
links the intracellular cytoskeleton (via dystrophin or utro-
phin) to the extracellular matrix (via laminin, agrin, or per-
lecan). Impairment of this linkage is instrumental in the
pathogenesis of muscular dystrophies. In brain, dystroglycan
and dystrophin are expressed on neurons and astrocytes,
and some muscular dystrophies cause cognitive dysfunc-
tion; however, no extracellular binding partner for neu-
ronal dystroglycan is known. Regular components of the
extracellular matrix, such as laminin, agrin, and perlecan,
 
are not abundant in brain except in the perivascular space
that is contacted by astrocytes but not by neurons, suggest-
ing that other ligands for neuronal dystroglycan must exist.
We have now identiﬁed 
 
 
 
- and 
 
 
 
-neurexins, polymorphic
neuron-speciﬁc cell surface proteins, as neuronal dystro-
I
 
glycan receptors. The extracellular sequences of 
 
 
 
- and
 
 
 
-neurexins are largely composed of laminin-neurexin–sex
hormone–binding globulin (LNS)/laminin G domains, which
are also found in laminin, agrin, and perlecan, that are dys-
troglycan ligands. Dystroglycan binds speciﬁcally to a sub-
set of the LNS domains of neurexins in a tight interaction
that requires glycosylation of dystroglycan and is regulated
by alternative splicing of neurexins. Neurexins are receptors
 
for the excitatory neurotoxin 
 
 
 
-latrotoxin; this toxin com-
petes with dystroglycan for binding, suggesting overlapping
binding sites on neurexins for dystroglycan and 
 
 
 
-latrotoxin.
Our data indicate that dystroglycan is a physiological ligand
for neurexins and that neurexins’ tightly regulated interac-
tion could mediate cell adhesion between brain cells.
 
Introduction
 
Neurexins are neuron-specific cell surface proteins (for re-
view see Missler and Südhof, 1998a). Neurexins are ex-
pressed in hundreds of alternatively spliced isoforms that are
developmentally and spatially regulated, suggesting a role in
regulated cell–cell interactions (Ushkaryov et al., 1992,
1994; Ushkaryov and Südhof, 1993; Ullrich et al., 1995).
All three vertebrate genes for neurexins contain two indepen-
dent promoters that direct synthesis of the longer 
 
 
 
-neurex-
ins and the shorter 
 
 
 
-neurexins. 
 
 
 
-Neurexins are composed
of a large extracellular sequence that includes six laminin-
neurexin–sex hormone–binding globulin (LNS)*/laminin G
(LG) domains with three interspersed EGF-like regions; in
contrast, 
 
 
 
-neurexins contain only a single LNS domain and
no EGF-like sequences (see Fig. 1). LNS domains are widely
distributed globular domains that are named for the proteins
in which they were originally defined and are also referred to
as LG domains (for review see Missler and Südhof, 1998a;
Timpl et al., 2000). Following the LNS domains, both 
 
 
 
- and
 
 
 
-neurexins contain a glycosylation sequence, a single trans-
membrane region, and a short intracellular tail (see Fig. 1).
The receptor-like structures of neurexins, their highly
polymorphic nature, and the spatial segregation of their
splice forms led to the suggestion that neurexins function as
cell adhesion and cell recognition molecules whose extracel-
lular interactions are regulated by alternative splicing. In
support of this hypothesis, 
 
 
 
-neurexins bind to neuroligins,
neuronal cell surface proteins that are concentrated in the
postsynaptic density of excitatory synapses (Ichtchenko et
al., 1995, 1996; Song et al., 1999). Binding of 
 
 
 
-neurexins
to neuroligins is dependent on alternative splicing and re-
sults in the formation of a cell adhesion junction (Irie et
al., 1997; Nguyen and Südhof, 1997; Butz et al., 1998;
Scheiffele et al., 2000). In contrast to 
 
 
 
-neurexins, 
 
 
 
-neur-
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exins have no currently known extracellular cell adhesion
partner, although they are more polymorphic than 
 
 
 
-neur-
exins and are at least as abundant. The only characterized
physiological ligands for 
 
 
 
-neurexins are neurexophilins,
small secreted glycoproteins that bind to the second LNS
domain of 
 
 
 
-neurexins in a splice site–independent manner
(Petrenko et al., 1996; Missler and Südhof, 1998b; Missler
et al., 1998). In addition, both 
 
 
 
- and 
 
 
 
-neurexins are high
affinity receptors for 
 
 
 
-latrotoxin, an excitatory neurotoxin
from black widow spider venom that triggers synaptic vesicle
exocytosis (Davletov et al., 1995; Sugita et al., 1999). Based
on their structure and distribution, it appears likely that
 
 
 
-neurexins can also function as cell adhesion molecules,
but no binding partner for such a role is known.
Like neurexins, dystroglycan is also a cell surface protein.
However, unlike neurexins dystroglycan is expressed ubiqui-
tously and is composed of two invariable subunits, 
 
 
 
- and
 
 
 
-dystroglycan, that are derived by proteolytic cleavage from
a single dystroglycan precursor and remain bound to each
other on the cell surface (Ibraghimov-Beskrovnaya et al.,
1992, 1993). The 
 
 
 
-dystroglycan subunit contains an au-
tonomously folded NH
 
2
 
-terminal domain and a highly gly-
cosylated sequence (Brancaccio et al., 1997) and accounts
for almost the entire extracellular part of dystroglycan. In
contrast, the 
 
 
 
-dystroglycan subunit is composed of a single
transmembrane region and a cytoplasmic tail with little ex-
tracellular sequence. The function of dystroglycan has been
well defined in embryonic development and in mature mus-
cle cells (for reviews see Hemler, 1999; Henry and Camp-
bell, 1999). Extracellularly, dystroglycan binds to the LNS
domains of several extracellular matrix proteins, namely
laminin, agrin, and perlecan (Ervasti and Campbell, 1993;
Bowe et al., 1994; Campanelli et al., 1994; Gee et al., 1994;
Peng et al., 1998; Henry et al., 2001). Intracellularly, it
binds to dystrophin and utrophin, which in turn are con-
nected to the actin cytoskeleton (Ibraghimov-Beskrovnaya et
al., 1992, 1993; Ahn and Kunkel, 1993). By virtue of these
interactions, dystroglycan links the intracellular actin cyto-
skeleton to the extracellular matrix, especially the basal lam-
ina, and thereby connects cells mechanically in the context
of an overall tissue. Dystroglycan function is essential, since
its deletion leads to early embryonic lethality (Henry and
Campbell, 1998). In addition, muscle dystroglycan is re-
quired for normal neuromuscular junction formation (Peng
et al., 1999; Grady et al., 2000).
Dystrophin and dystroglycan are expressed abundantly in
neurons where their function is unknown (Lidov et al., 1990;
Kim et al., 1992; Ibraghimov-Beskrovnaya et al., 1993; Tian
et al., 1996; Blake and Kröger, 2000). The extracellular space
between neurons in adult brain lacks a basal lamina and does
not contain the classical extracellular matrix proteins laminin,
perlecan, collagen, or agrin (Jucker et al., 1996; Ruoslahti,
1996). Basal lamina in brain delineate blood vessels, which
are contacted by astrocytic “feet” extensions but have no di-
rect connections with neurons. Thus, dystroglycan in neu-
rons has no known extracellular-binding partner, and its role
is obscure. However, the function of neuronal dystroglycan
may potentially be important not only for insight into neu-
ronal cell biology but also for understanding muscular dys-
trophies, since these are often associated with cognitive im-
 
pairment (Bresolin et al., 1994; Davies, 1997). In the present
study, in a search for endogenous ligands of 
 
 
 
-neurexins we
identified dystroglycan as the major interacting partner. Ex-
tensive studies showed that dystroglycan binds tightly to sin-
gle LNS domains in both 
 
 
 
- and 
 
 
 
-neurexins in a manner
regulated by alternative splicing. Our studies suggest a novel
role for dystroglycan in neurons as intercellular cell adhesion
molecules by binding to neurexins.
 
Results
 
We chose a biochemical approach to search for endogenous
ligands of 
 
 
 
-neurexins. Using transfected COS cells, we pro-
duced a series of Ig fusion proteins in which sequences from
 
 
 
- and 
 
 
 
-neurexins were linked to the human Ig Fc fragment
(Fig. 1). The largest neurexin Ig fusion protein (Ig–N1
 
 
 
-1)
contained almost the complete extracellular sequence of neur-
exin 1
 
 
 
, whereas the control Ig fusion protein (Ig–control)
included only the signal peptide and 18 NH
 
2
 
-terminal
amino acids of neurexin 1
 
 
 
 (Fig. 1). To identify 
 
 
 
-neurexin
ligands, we immobilized purified Ig–N1
 
 
 
-1 and Ig–control
protein on protein A–Sepharose and employed them in af-
finity chromatography experiments. Proteins in total rat
brain homogenates were applied to the Ig fusion protein–
Sepharose matrix in the presence of Ca
 
2
 
 
 
, the Sepharose was
washed extensively, and bound proteins were eluted in high
salt buffer with and without Ca
 
2
 
 
 
. The eluents were analyzed
on silver-stained SDS-gels, revealing two major proteins in
the eluents from the Ig neurexin–Sepharose that were absent
from the control eluents (molecular weights 
 
 
 
43 and 
 
 
 
120
kD; Fig. 2). These proteins were identified as 
 
 
 
- and 
 
 
 
-dys-
troglycan by amino acid sequencing and immunoblotting
(unpublished data). In addition, both the neurexin and con-
trol eluents contained IgG heavy (IgG–HC) and light chains
(IgG–LC) that were presumably bound to the protein A–Seph-
arose from the rat brain homogenate and minor bands of un-
known provenance.
The affinity chromatography experiments suggested that
 
 
 
- and 
 
 
 
-dystroglycan are the only abundant rat brain pro-
teins which interact strongly with the neurexin 1
 
 
 
 Ig fusion
protein (Fig. 2). To explore the specificity and tightness of
dystroglycan binding to neurexin 1
 
 
 
, we probed the flow-
through, washes, and high salt eluents of similar affinity
chromatography experiments by immunoblotting. These re-
sults confirmed that the neurexin 1
 
 
 
 column but not the
control column strongly bound 
 
 
 
- and 
 
 
 
-dystroglycan (Fig.
3). Strikingly, 
 
 
 
- and 
 
 
 
-dystroglycan were quantitatively re-
moved from the flow-through of the neurexin 1
 
 
 
 column,
demonstrating that dystroglycan binding to neurexin 1
 
 
 
 is
of high affinity (Fig. 3, lane 2). No binding of neuroligin 1
to neurexin 1
 
 
 
 was observed as expected from previous re-
sults showing that only 
 
 
 
-neurexins bind to neuroligins
(Ichtchenko et al., 1995, 1996).
We next asked if native neurexin and dystroglycan form a
physiological complex in brain. For this purpose, we immu-
noprecipitated 
 
 
 
- and 
 
 
 
-neurexins from brain homogenates
with antibodies to the intracellular COOH terminus that is
identical for both classes of neurexins (Fig. 1), using preim-
mune serum as a negative control (Hata et al., 1993). Pro-
teins coimmunoprecipitated with 
 
 
 
- and 
 
 
 
-neurexins were
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eluted with Ca
 
2
 
 
 
-free high salt buffer. Immunoblotting of
the eluted proteins revealed that 
 
 
 
-dystroglycan and neuro-
ligin 1 were highly enriched in the immunoprecipitates with
the neurexin antibody but were absent from the immuno-
precipitates with preimmune serum (Fig. 4). Synaptophysin
and syntaxin, abundant synaptic proteins that are relatively
“sticky,” were not brought down, confirming the specificity
of the immunoprecipitation.
The immunoprecipitation and affinity chromatography
experiments suggest that neurexins and dystroglycan form a
stoichiometric complex in brain and that dystroglycan could
constitute a cell surface receptor for 
 
 
 
-neurexins. To test this
directly, we made use of embryonic stem (ES) cells that are
heterozygous (DG
 
 
 
/
 
 
 
) or homozygous (DG
 
 
 
/
 
 
 
) for a null
mutation in the dystroglycan gene and either express or lack
dystroglycan on the surface (Henry and Campbell, 1998).
We partially purified dystroglycan from the ES cells by WGA
affinity chromatography, separated the ES cell proteins on an
SDS-gel, and blotted them onto PVDF membranes. The
membranes were then probed with purified Ig–N1
 
 
 
-1 in an
overlay assay and with antibodies to 
 
 
 
-dystroglycan as a con-
trol (Fig. 5 A). We detected a single 130-kD protein that was
bound by neurexin 1
 
 
 
 Ig fusion protein and was absent from
the dystroglycan-deficient cells (Fig. 5 A). The same 130-kD
protein reacted with 
 
 
 
-dystroglycan antibodies, suggesting
that neurexin 1
 
 
 
 directly binds to 
 
 
 
-dystroglycan. We next
examined if the neurexin Ig fusion protein binds specifically
to the surface of cultured ES cells, using Ig–control protein as
a negative control. Indeed, neurexin 1
 
 
 
 Ig fusion protein
only bound to ES cells containing dystroglycan but not to ES
cells lacking dystroglycan; no binding of the Ig–control pro-
 
tein was observed (Fig. 5 B). Binding occurred in patches on
the cell surface, suggesting that the neurexin 1
 
 
 
 Ig fusion
protein may cluster dystroglycan (Fig. 5 C). Together, these
data demonstrate that endogenous dystroglycan on ES cells is
a functional cell surface receptor for exogenous neurexin 1
 
 
 
.
Dystroglycan is a glycoprotein in which the 
 
 
 
-subunit car-
ries an uncommon 
 
O
 
-mannosyl modification that is required
for laminin binding and exhibits tissue-specific differences
(Ibraghimov-Beskrovnaya et al., 1992, 1993; Ervasti and
Campbell, 1993; Chiba et al., 1997). To test if dystroglycan
glycosylation is involved in neurexin binding, we partially pu-
rified dystroglycan from mouse brain, skeletal and cardiac
muscle, and lung tissue by WGA affinity chromatography.
The partially purified proteins were then analysed with the
neurexin overlay assay, using immunoblotting for 
 
 
 
- and
 
 
 
-dystroglycan as a control. In the various tissues examined,
 
 
 
-dystroglycan exhibited distinct electrophoretic mobility pat-
terns consistent with differential glycosylation, whereas 
 
 
 
-dys-
troglycan was constant as expected (Fig. 6 A). With the neur-
exin Ig fusion protein overlay assay, we observed specific
binding of neurexin 1
 
 
 
 to 
 
 
 
-dystroglycan in brain and muscle
but not in lung. In brain and muscle, 
 
 
 
-dystroglycan was the
only protein in the WGA protein fraction that bound neur-
exin 1
 
 
 
 (Fig. 6 A). Although fully reactive with antibodies,
lung 
 
 
 
-dystroglycan did not bind to neurexin 1
 
 
 
. To test the
effect of dystroglycan glycosylation on neurexin 1
 
 
 
 binding,
we first deglycosylated the WGA-purified proteins from brain
and lung with a mixture of glycolytic enzymes that cleave N-
and O-linked sugars (endoglycosidase F, sialidase, and 
 
O
 
-gly-
canase) (Fig. 6 B). Enzymatic deglycosylation led to a small
shift in the apparent size of 
 
 
 
-dystroglycan, presumably be-
Figure 1. Domain structures of a- and b-neurexins 
(top) and locations of Ig and GST fusion proteins used 
for binding studies (bottom). Principal features of neu-
rexins are indicated on top: SP, signal peptide; LNS, 
LNS domains, named after laminin G-domain repeats, 
neurexins, and sex hormone–binding globulin, and also 
referred to as LG domains; EGF, EGF-like sequences; 
CHO, carbohydrate attachment site; T, transmembrane 
region; numbered arrows, positions of canonical alter-
native splice sites (Ullrich et al., 1995). The regions of 
neurexins included in the various Ig and GST fusion 
proteins are displayed below the neurexin diagram; 
these proteins are named after the neurexin from 
which they were derived, followed by a unique identi-
fying number. The splice site inserts contained in the 
fusion proteins are indicated above the lines. A single 
variant for splice site no. 1 (which is not in an LNS do-
main) was analysed ( , B-variant; Ullrich et al., 1995) 
and three variants for splice site no. 2 in which “ ” cor-
responds to the no-insert variant, “ ” to the small insert 
(sequence in neurexin 1 : HSGIgHAM), and “  ” to 
the large insert (sequence in neurexin 1 : HSGIgHAM-
VNKLHCS). Two variants were studied for splice site 
nos. 3 and 4 (“ ,” 3 residue insert for splice site no 3 
and 30 residues for splice site no. 4; “ ,” no insert).
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cause only part of the complex carbohydrates are removed (Er-
vasti and Campbell, 1993). Enzymatic deglycosylation had lit-
tle effect on neurexin 1  binding to brain  -dystroglycan but
surprisingly activated neurexin 1  binding to lung  -dystro-
glycan, suggesting that lung  -dystroglycan was inactive be-
cause of a particular form of glycosylation (Fig. 5 B). We also
performed complete deglycosylations of  -dystroglycan using
trifluoromethanesulfonic acid (TFMS). Chemical deglycosyla-
tion caused a major decrease in the electrophoretic mobility of
 -dystroglycan as described (Ervasti and Campbell, 1993) and
completely abolished neurexin 1  binding as measured by the
overlay assay in both brain and lung (Fig. 6 B). These data in-
dicate that neurexin 1  interacts with  -dystroglycan only
when  -dystroglycan is properly and specifically glycosylated.
Which domain of neurexin 1  binds to dystroglycan, do
other neurexins also bind to dystroglycan, and are the inter-
actions of dystroglycan with neurexins regulated by alterna-
tive splicing of neurexins? To address these questions, we
employed a series of shorter Ig fusion proteins of neurexins
that incorporate a subset of the neurexin domains with se-
lected splice variants (schematically described in Fig. 1). We
tested which of these proteins bind to dystroglycan by im-
mobilizing equivalent amounts of Ig fusion proteins on pro-
tein A–Sepharose for affinity chromatography experiments.
Rat brain proteins were then applied to the columns in the
presence and absence of Ca
2 , and bound proteins were
analysed by immunoblotting. A highly selective pattern of
dystroglycan-binding emerged: only  -neurexins contain-
ing the second or the sixth LNS domain captured dystro-
glycan (Fig. 7 A). A single isolated LNS domain without
flanking sequences fully bound to dystroglycan in a Ca
2 -
dependent reaction. The second LNS domain of all three
 -neurexins (neurexin 1 , 2 , and 3 ) formed tight Ca
2 -
dependent complexes with dystroglycan, suggesting that all
 -neurexins bind to dystroglycan (Fig. 7 A). Furthermore,
neurexin 1  (which contains only a single LNS domain that
corresponds to the sixth LNS domain of neurexin 1 ) also
captured dystroglycan. These results suggest that both  -
and  -neurexins bind to dystroglycan and confirm that a
single LNS domain contains all information required for
dystroglycan binding. Nevertheless, not all LNS domains in-
Figure 2. Affinity purification of dystroglycan on Ig–neurexin
analyzed by SDS-PAGE and silver staining. Solubilized proteins 
from total rat brain homogenate (lane 1) were applied in 0.1 M 
NaCl and 2.0 mM Ca
2  buffer to a column containing immobilized 
Ig–N1 -1 or Ig–control proteins, and the flow-through was col-
lected (lane 2). The column was washed extensively with loading 
buffer (lane 3) and 0.2 M NaCl, 2.0 mM Ca
2  buffer (not shown), 
and eluted with 1.0 M NaCl, 2.0 mM Ca
2  buffer (lane 4) followed 
by 1.0 M NaCl, 5 mM EGTA buffer (lane 5). Fractions were analyzed 
by SDS-PAGE and silver staining. The 120- and 43-kD proteins only 
present in the Ig–N1 -1 eluent correspond to  - and  -dystroglycan 
( -DG and  -DG). IgG-HC and IgG-LC, respectively, and minor 
contaminants (for example, the 75-kD band labeled with an aster-
isk) were equally retained on the neurexin and the control column, 
presumably by binding to protein A–Sepharose.
Figure 3. Quantitative binding of rat brain dystroglycan to immo-
bilized neurexin 1  analyzed by immunoblotting. Rat brain pro-
teins were bound to columns containing immobilized Ig–N1 -1 or 
Ig–control proteins, washed twice in binding buffer (Wash 1 and 2), 
and eluted with 1.0 M NaCl, 5 mM EGTA (Elution). Identical 
amounts of the various fractions were analyzed by immunoblotting 
for  - and  -dystroglycan and neuroligin 1. Note that dystroglycan 
is quantitatively depleted from the homogenates in the flow-through 
of the Ig–neurexin column, whereas neuroligin does not bind to 
neurexin 1  as shown previously (Ichtchenko et al., 1995, 1996). 
Numbers at the left in both panels indicate positions of molecular 
weight markers.
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teract with dystroglycan, since the first, third, fourth, and
fifth LNS domains of neurexin 1  were inactive.
The neurexin Ig fusion proteins employed for the experi-
ments in Fig. 7 A not only incorporate different LNS do-
mains but also different splice variants of these domains.
The second and sixth LNS domain of  -neurexins (the latter
being identical with the single LNS domain of  -neurexins)
are both alternatively spliced (Ullrich et al., 1995). Interest-
ingly, for both LNS domains alternative splicing tightly reg-
ulated dystroglycan binding. Only the splice variants of
these LNS domains that lack an insert interacted with dys-
troglycan (Fig. 7, A and B). Although the sites of alternative
splicing are at different positions in the sequences of the sec-
ond and sixth LNS domains, the crystal structure of the
sixth LNS domain of neurexin 1  (Rudenko et al., 1999)
showed that both splice sites are located in close proximity
on the surface of the folded domain, suggesting that this lo-
cation represents the binding site for dystroglycan. In the
second LNS domain, the smallest splice insert contains only
eight amino acids, indicating that a small change in the
binding surface abolishes binding. These findings indicate
that the regulated alternative splicing of neurexins can con-
trol their interactions with dystroglycan (Fig. 7).
The binding of neurexins to dystroglycan resembles bind-
ing of laminin, which is also Ca
2 -dependent and mediated
by LNS domains (for review see Timpl et al., 2000) but dif-
fers from laminin binding in that the alternative splicing of
the neurexin LNS domains controls dystroglycan binding
(Fig. 7 A). In the LNS domains from laminin, a Ca
2 -bind-
ing site was defined structurally, and the residues involved in
Ca
2 -binding are conserved in the neurexin LNS domains
(Hohenester et al., 1999; Rudenko et al., 1999; Tisi et al.,
2000). To examine if the second LNS domain of neurexin
1  contains an analogous Ca
2 -binding site, we mutated one
of the aspartate residues of the putative Ca
2 -binding site to
asparagine. We then used glutathione S-transferase (GST)
fusion proteins of wild-type and mutant LNS domains to
test  -dystroglycan binding (Fig. 7 B). As with the Ig fusion
proteins, the GST fusion protein bound dystroglycan in a
Ca
2 -dependent manner; binding was completely abolished
by the Ca
2 -binding site mutant. Furthermore, GST fusion
proteins of the splice variants of the second LNS domain
that were inactive in the Ig fusion proteins were also inactive
in the GST fusion proteins (Fig. 7 B). Among others, these
experiments suggest that neurexin LNS domains have Ca
2 -
binding sites similar to those of laminin but do not have to
be glycosylated in order to bind to dystroglycan, since the
bacterial GST fusion proteins are unlikely to be glycosylated.
Our data indicate the possibility that dystroglycan, cur-
rently known as an anchor protein for the extracellular matrix
in nonneuronal cells but not as a cell adhesion molecule, may
function in brain by interacting with neuron-specific neurex-
ins. This hypothesis implies that brain dystroglycan should be
expressed in a developmental profile similar to that of neurex-
ins if they functionally cooperate. Indeed, immunoblot analy-
sis of rat brain proteins at different stages of postnatal devel-
opment revealed parallel expression of dystroglycan and
neurexins (Fig. 8).  -Dystroglycan and  - and  -neurexins
were of low abundance prenatally, increased dramatically af-
ter birth, and experienced peak expression during the second
postnatal week, a period of intense synaptogenesis. Thereaf-
ter, the levels of dystroglycan and neurexins declined together
to a steady-state level that was approximately half of peak
abundance at the end of the second postnatal week (Fig. 8,
P15). This expression profile was different from that of lami-
nin, a ligand for dystroglycan in basement membranes, which
was expressed at a relatively constant low level similar to the
ubiquitous control protein VCP. By contrast, synaptotagmin
exhibited a cumulative increase in expression during develop-
ment, in parallel with the continuous accumulation of synap-
tic vesicles in presynaptic nerve terminals as synapses mature.
Together, these results suggest that  - and  -neurexins
represent ligands for dystroglycan via interactions of their
LNS domains, analogous to interaction of the LNS-domain
in laminin, agrin, and perlecan with dystroglycan. The tight
regulation of the neurexin–dystroglycan interaction by alter-
native splicing of neurexins is similar to the binding of
 -latrotoxin to neurexins, which also requires variants lack-
ing an insert in the site of alternative splicing in the sixth
LNS domain (Sugita et al., 1999). We therefore tested if
 -latrotoxin competes with dystroglycan for neurexin bind-
ing. Dystroglycan from rat brain homogenates was bound to
immobilized neurexin 1 , and the ability of  -latrotoxin to
displace dystroglycan in a concentration-dependent manner
was tested (Fig. 9). In the absence of  -latrotoxin, dystrogly-
can was stably bound to the Ig neurexin fusion protein.
However, addition of increasing concentrations of  -latro-
toxin released dystroglycan into the supernatant, suggesting
Figure 4. Coimmunoprecipitation of neurexins with dystroglycan 
and neuroligin 1 from brain. Neurexin antibodies or preimmune 
sera were immobilized on protein A–Sepharose and incubated with 
rat brain proteins solubilized from synaptosomes (lane 1). After ex-
tensive washing (lanes 2–4), the protein A–Sepharose column was 
eluted with buffer containing 1.0 M NaCl, 5 mM EDTA (lane 5). The 
final wash and the EDTA eluent were concentrated with TCA, and 
equivalent aliquots were analyzed by immunoblotting with antibod-
ies to the indicated proteins.
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that  -latrotoxin and dystroglycan bind to the same site on
neurexins.  -Latrotoxin binds to two separate high affinity
receptors in brain, neurexins, and CLs (CIRL/latrophilins)
(Ushkaryov et al., 1992; Krasnoperov et al., 1997; Lelianova
et al., 1997; Sugita et al., 1998, 1999). To investigate if dys-
troglycan may be a general endogenous ligand for high affin-
ity  -latrotoxin–binding sites, we tested binding of dystro-
glycan to an Ig fusion protein of the extracellular sequences
of CL1 but detected no binding (unpublished data). This is
consistent with the fact that CL1 contains no LNS domains
and binds to  -latrotoxin via a distinct mechanism.
Discussion
Our data demonstrate that dystroglycan and neurexins form
a stoichiometric Ca
2 -dependent complex in brain. This
conclusion is supported by the following evidence. (a) Affin-
ity chromatography on immobilized neurexin 1  purified
 - and  -dystroglycan as major binding proteins (Fig. 2).
(b) Immobilized neurexin 1  quantitatively removed  -dys-
troglycan from brain homogenates, indicating complete
binding (Fig. 3). (c) Neurexins are coimmunoprecipitated
with  - and  -dystroglycans from brain homogenates (Fig.
4). (d) The neurexin 1  overlay assay revealed specific bind-
ing of neurexin 1  to  -dystroglycan in ES cells (Fig. 5 A)
and in mouse tissues (Fig. 6 A). (e) A soluble recombinant
neurexin 1  Ig fusion protein specifically bound to the sur-
face of cells expressing dystroglycan but not to cells lacking
dystroglycan (Fig. 5 B). (f) Finally, the excitatory neurotoxin
 -latrotoxin, which is a natural ligand for neurexins (Ush-
karyov et al., 1992; Sugita et al., 1999), competes with dys-
troglycan for binding to neurexins (Fig. 9).
The neurexin–dystroglycan complex has several poten-
tially interesting characteristics. The second and sixth LNS
domains of  -neurexins and the single LNS domain of
 -neurexins specifically bind to  -dystroglycan in a manner
that is regulated by alternative splicing in an all-or-none
fashion (Fig. 7, A and B). Thus, a single  -neurexin mole-
Figure 5. Binding to neurexin 1  to ES cells that express or lack dystroglycan. (A) Neurexin overlay analysis. Proteins were isolated by 
WGA affinity chromatography from ES cells that are heterozygous (DG
 / ) or homozygous mutant (DG
 / ) for the dystroglycan gene and an-
alyzed by immunoblotting with an antibody to  -dystroglycan (top) or by the neurexin overlay assay using Ig–N1 -1 (bottom). Note that the 
neurexin Ig fusion protein only reacts with  -dystroglycan in the heterozygous mutant but not the homozygous mutant ES cells. (B and C) Cell 
surface binding. Cultured heterozygous and homozygous mutant ES cells containing or lacking dystroglycan (DG
 /  or DG
 / , respectively) 
were reacted with Ig–control or Ig–N1 -1. Phase–contrast images are shown above the corresponding immunofluorescence images for each 
condition; cell boundaries are identified by arrows. Note that both dystroglycan and neurexin 1  are required to obtain cell surface reactivity. 
C depicts a high magnification view of a single dystroglycan-positive ES cell reacted with Ig–N1 -1 to highlight clustered neurexin/dystrogly-
can complexes on the cell surface. Bars, 10  m.
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cule can potentially bind multiple dystroglycans, which may
explain the patchy appearance of bound neurexin on the sur-
face of dystroglycan-expressing cells (Fig. 5 C). The fact that
only an alternatively spliced subset of neurexins is capable of
complexing with dystroglycan on the cell surface indicates
that use of splice variants regulates neuronal interactions
with dystroglycan. Glycosylation of dystroglycan is required
for neurexin to bind. Dystroglycan exhibits tissue-specific
differences in glycosylation (Ibraghimov-Beskrovnaya et al.,
1992, 1993) that may be functionally relevant, since native
lung dystroglycan was unable to bind to neurexin 1  but
was activated by partial deglycosylation (Fig. 6 B). However,
neurexin glycosylation is not required for dystroglycan bind-
ing, since bacterially expressed LNS domain from neurexin
1  was fully active (Fig. 7 B).
Neurexins constitute the first neuronal dystroglycan
ligands that are also cell surface proteins. Conversely, dystro-
glycan is the first transmembrane ligand for  -neurexins that
could involve  -neurexins in cell–cell interactions similar to
the binding of neuroligins to  -neurexins (Ichtchenko et al.,
1995, 1996; Irie et al., 1997; Nguyen and Südhof, 1997).
The binding of neuroligins to  -neurexins has been impli-
cated in synaptogenesis because neuroligins are highly en-
riched in postsynaptic densities (Ichtchenko et al., 1995;
Song et al., 1999), the interaction of neuroligins with
 -neurexins results in the formation of an intercellular junc-
tion that is coated on both sides by PDZ domain proteins
(Irie et al., 1997; Butz et al., 1998), and expression of neuro-
ligin in fibroblasts induces presynaptic specializations in
nerve terminals that contact these fibroblasts (Scheiffele et
al., 2000). It is possible that the interaction of dystroglycan
with neurexins has a similar role in synaptogenesis or that
this interaction serves in other contacts of neurons with each
other or with astrocytes. Ultrastructural localization of neur-
exins and dystroglycan would be very helpful here but has
proved exceedingly difficult especially for neurexins because
we and others have been unable until now to raise antibodies
with high enough affinity for EM.
In nonneuronal cells, the primary function of dystrogly-
can is to provide a transmembrane link between the extracel-
lular matrix, especially basal lamina, and the intracellular ac-
tin cytoskeleton (for reviews see Hemler, 1999; Henry and
Campbell, 1999). However, in fully developed brain neu-
rons are not in direct contact with basement membranes
or other types of extracellular matrix–containing laminin,
agrin, or perlecan, the currently known ligands for dystro-
glycan (Ervasti and Campbell, 1993; Gee et al., 1993; Cam-
panelli et al., 1996; Gesemann et al., 1996; Jucker et al.,
1996; Ruoslahti, 1996; Tian et al., 1996; Peng et al., 1998;
Serpinskaya et al., 1999; Talts et al., 1999). Thus, the pri-
mary function of dystroglycan in nonneuronal cells, to at-
tach cells to the extracellular matrix, does not apply to neu-
rons. Our results suggest that one of the ligands with which
dystroglycan interacts in brain may be neurexins, thereby
providing an explanation for the abundant expression of
dystroglycan in neurons where its biological role is unknown
(Lidov et al., 1990; Ibraghimov-Beskrovnaya et al., 1992,
1993; Tian et al., 1996; Blake and Kröger, 2000).
Although functionally different, the binding of dystrogly-
can to the LNS domains of neurexins follows the same para-
digm as the binding of dystroglycan to the LNS domains in
laminin and agrin, all of which bind to dystroglycan in a
Ca
2 -dependent reaction that requires glycosylation of dys-
troglycan and that is mediated by single LNS domains. The
three-dimensional structures of LNS domains uncovered a
similarity with lectins (Hohenester et al., 1999; Rudenko et
al., 1999; Grishkovskaya et al., 2000), consistent with the
notion that the carbohydrates on dystroglycan are bound di-
rectly by the LNS domain. Furthermore, a Ca
2 -binding site
was observed in the laminin LNS domain (Hohenester et al.,
1999), and our mutational analysis indicates that neurexin
LNS domains have a similar Ca
2 -binding site (Fig. 7 B).
Together, these data suggest a unitary structural mechanism
by which LNS domains bind to dystroglycan; possibly other
LNS domain proteins, such as NG2, CASPR, or slit (Roth-
Figure 6. Tissue-specific glycosylation controls binding of neur-
exin 1  to  -dystroglycan. (A) Tissue distribution. Equivalent 
amounts of proteins isolated by WGA affinity chromatography from 
mouse brain, skeletal muscle, cardiac muscle, and lung were ana-
lyzed by immunoblotting with antibodies to  - and  -dystroglycan 
( -DG and  -DG) and by the neurexin overlay assay with Ig–N1 -1. 
(B) Effect of deglycosylation. Mouse brain and lung proteins were en-
zymatically deglycosylated by treatment with N-glycosidase F, siali-
dase and O-glycosidase (left) or chemically deglycosylated by treat-
ment with trifluoromethanesulfonic acid (right). Proteins were 
separated by SDS-PAGE, and  -dystroglycan was detected by immu-
noblotting ( -DG antibody) or by neurexin 1  overlay assay with
Ig–N1 -1. Note that enzymatic deglycosylation (which only removes 
part of the complex sugars) activates neurexin 1  binding to lung dys-
troglycan, whereas complete chemical deglycosylation inhibits neur-
exin 1  binding without abolishing immunoreactivity. For all panels, 
numbers on the left indicate positions of the molecular weight markers.
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berg et al., 1990; Nishiyama et al., 1991; Peles et al., 1997),
may also bind. However, our results also reveal an unex-
pected versatility of LNS domains. The second LNS domain
of  -neurexins interacts with two proteins, dystroglycan
and neurexophilin, via distinct mechanisms. Neurexophilin
binds to the second LNS domain independent of Ca
2  and
irrespective of alternative splicing (Missler and Südhof,
1998b; Missler et al., 1998), whereas dystroglycan binding
requires Ca
2  and is regulated by alternative splicing. This
suggests that neurexophilin and dystroglycan contact dis-
tinct sites in the second LNS domain. The sixth LNS do-
main of  -neurexins, simultaneously the only LNS domain
of   -neurexins, also participates in multiple interactions,
namely with dystroglycan, neuroligins, and  -latrotoxin
(Ichtchenko et al., 1995, 1996; Sugita et al., 1999). These
interactions share the same Ca
2  requirement and regulation
by alternative splicing, indicating that all three ligands may
contact the same site on the surface of this LNS domain.
Dystroglycan and  -latrotoxin bind to either  - and  -neur-
exins without regard to flanking sequences, in agreement
with the finding that a single LNS domain is sufficient for
dystroglycan binding (Fig. 7). However, neuroligins only
bind to the  -neurexin LNS domain when it is preceded by
the short sequence unique to  -neurexins, which thus con-
fers specificity (Ichtchenko et al., 1995, 1996).
What is the function of the dystroglycan–neurexin com-
plex? The stoichiometric nature and abundance of the com-
plex suggest that it is physiologically important, but its local-
ization is unclear. Indirect evidence links neurexins and
dystroglycan to the synapse (Lidov et al., 1990; Ushkaryov et
al., 1992; Hsueh et al., 1998; Song et al., 1999; Sugita et al.,
1999; Blake and Kröger, 2000), an interesting possibility in
view of the cognitive disorders associated with some cases of
muscular dystrophy in which the dystroglycan-binding pro-
tein dystrophin is mutated (Bresolin et al., 1994). Both dys-
troglycan and  -neurexins are essential genes required for vi-
ability (Henry and Campbell, 1998). Although in mice
dystrophin is not necessary for normal neuronal function,
possibly because of redundancy, dystrophin-deficient mice
exhibit a mislocalization of synaptic  -aminobutyric acid re-
ceptors (Knuesel et al., 1999, 2001). This indicates that the
dystrophin-related complex may be required for the proper
localization of proteins to postsynaptic density in central
synapses, similar to the role of postsynaptic dystroglycan in
neuromuscular junctions (Grady et al., 2000). A synaptic cell
adhesion complex composed of dystroglycan and neurexins
would be ideally suited for synaptic interactions because sim-
ilar to synapses this complex is asymmetric. Furthermore, the
regulation of this complex by alternative splicing of neurex-
ins could provide a mechanism of control whereby the type
Figure 7. Determinants of  -dystroglycan binding in the neurexin 
LNS domains. (A) Effect of alternative splicing. Equivalent amounts 
of the immobilized Ig–neurexin proteins as indicated (see Fig. 1 for a 
precise location of these proteins) were incubated with total rat brain 
homogenate in the presence and absence of Ca
2 . Bound proteins 
were analysed by SDS-PAGE and immunoblotting for  -dystroglycan 
( -DG; top) or Coomassie blue staining (bottom; arrows indicate the 
positions of respective Ig–neurexins). The highly glycosylated  -dys-
troglycan is poorly visible on the Coomassie-stained gel because 
small amounts of brain extracts were used, whereas all columns bind 
relatively large amounts of immunoglobulins (IgG-HC) via protein
A–Sepharose.  -Dystroglycan binding is specific for constructs con-
taining either the second or sixth LNS domain of  -neurexins or the 
single LNS domain of  -neurexins, but binding only occurs when 
these LNS domains include no alternatively spliced insert. (B) A 
Ca
2 -binding site mutant abolishes binding. GST fusion proteins con-
taining the second LNS domain of neurexin 1  without an insert with 
the wild-type sequence (N1 -1) or with a point mutation in a putative 
Ca
2 -binding site (N1 -1
D345N) and of the second LNS domain with 
the short (N1 -2) or long insert (N1 -3) and GST alone were used in 
pulldown experiments with brain homogenates with and without 
Ca
2 . Bound proteins were analysed by immunoblotting with anti-
bodies to  -dystroglycan (top) or Coomassie blue staining (bottom).
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of alternative splicing would dictate the intercellular interac-
tions of a neuron, and the polymorphism of neurexins would
translate into a recognition code. Finally, our results suggest
a mechanism by which some forms of muscular dystrophy
could give rise to cognitive dysfunction, namely via a defec-
tive linkage of the dystroglycan–neurexin complex to dystro-
phin. However, these are speculative hypotheses at present
that have to be explored in future studies.
Materials and methods
Construction of expression vectors and production 
of recombinant proteins
The following expression vectors for neurexin–Ig proteins constructed in
pCMV-Ig (Davletov et al., 1995; Ichtchenko et al., 1995, 1996; Missler et
al., 1998) were used (see Fig. 1 for the various splice variants present in
these constructs): pCMVIgL-C   Ig–control (residues 1–48 of rat neur-
exin 1 ; includes signal peptide and NH2-terminal 18 amino acids);
pCMVIgbN1 -1   Ig–N1 -1 (residues 1–1361 of bovine neurexin 1 );
pCMVIgbN1 -14 and -15   Ig–N1 -14 and -15 (residues 1–611 of bovine
neurexin 1 ); pCMVIgbN1 -18   Ig–N1 -18 (residues 1–207 of bovine
neurexin 1 ); pCMVIgbN1 -21, -24, and -25 = Ig–N1 -21, -24, and -25
(residues 298–506 of bovine neurexin 1  fused to residues 1–48 of rat
neurexin 1  as a signal peptide); pCMVbN1 -31 and -32   Ig–N1 -31
and -32 (residues 1–42 [as signal peptide] fused to residues 920–1,361 of
bovine neurexin 1 ); pCMVIgbN1 -37 and -38-2   Ig–N1 -37 and -38
(residues 1–42 fused to residues 738–931 of bovine neurexin 1 );
pCMVIgbN1 -39 and -40-2   Ig–N1 -39 and -40 (residues 1–42 fused to
residues 486–931 of bovine neurexin 1 ); pCMVIgN1 -1 and -3   Ig–
N1 -1 and -3 (residues 1–299 of rat neurexin 1 ); pCMVIgN2 -5   Ig–
N2 -5 (residues 288–493 of neurexin 2 ); pCMVIgN3 -6    Ig–N3 -6
(residues 265–455 of neurexin 3 ). Ig fusion proteins were produced by
transfection of the pCMVIg constructs into COS cells using DEAE-dextran
with chloroquine and a 2-min glycerol shock (Ichtchenko et al., 1995).
The supernatant of transfected COS cells was harvested 3–4 d after trans-
fection, adjusted to 10 mM Hepes-NaOH, pH 7.4, and 0.1 g/liter PMSF,
cleared by centrifugation (2,500 g), incubated overnight with protein
A–Sepharose (Amersham Pharmacia Biotech), and washed three times
with PBS before use in affinity chromatography experiments. The GST pro-
tein vectors pGexbN1 (2LNSA), pGexbN1 (2LNSB), pGexbN1 (2LNSC),
and pGexbN1 (2LNSA
D345N) were constructed in pGEX-KG and encode
GST-N1 -1, GST-N1 -2, GST-N1 -3, and GST-N1 -1
D345N that contain
the second LNS domain of bovine neurexin 1  (residues 293–491) with
the indicate splice variants and point mutation (Fig. 1).
Affinity chromatography experiments
For Ig fusion protein affinity chromatography, two frozen rat brains were
homogenized in 11 ml of 20 mM Hepes-NaOH, pH 7.4, 1 mM EGTA, and
0.1 g/liter PMSF, and an equal volume of the same buffer containing 0.2 M
NaCl, 2% Triton X-100 was added. The homogenate was extracted for 1 h
at 4 C, insoluble material was removed by centrifugation (30 min at
100,000 g), and 2.5 mM MgCl2 and 3.0 mM CaCl2 were added. Protein
A–Sepharose containing Ig–N1 -1 or Ig–control ( 80  g protein in 0.2 ml)
were preequilibrated with buffer A (20 mM Hepes-NaOH, pH 7.4, 0.1 M
NaCl, 1% Triton X-100, 2.5 mM MgCl2, 2 mM CaCl2), incubated overnight
at 4 C with 10 ml of the brain extract, centrifuged (800 g for 2 min), and
washed with 15 ml buffer A. Washed Sepharose was packed into polypro-
pylene columns with paper discs (Quick-Sep; Isolab), washed again with
buffer A (5 ml), and sequentially eluted with 4 ml of buffer A containing
0.2 M NaCl, 1.0 M NaCl, and 1.0 M NaCl with 5 mM EGTA instead of
CaCl2. Eluted proteins were TCA precipitated, resuspended in 200  l sam-
ple buffer, and 20  l were analyzed by SDS-PAGE and silver staining. The
120-kD protein that was affinity purified on the Ig–N1 -1 was cut out of
the gel, digested with trypsin, and tryptic fragments were purified by high
performance liquid chromatography and analyzed by Edman degradation
as described (Hata et al., 1993), identifying  -dystroglycan. The identity of
both dystroglycan subunits was then confirmed by immunoblotting with
specific antibodies. For analysis of how much of the dystroglycan in brain
extracts bound to Ig–neurexins, 1 ml each of the brain extract was incu-
bated with 20  g of Ig–N1 -1 or Ig–control protein immobilized on pro-
tein A–Sepharose, affinity chromatography was performed essentially as
above, and samples were analysed by SDS-PAGE and immunoblotting
with antibodies to  - and  -dystroglycan (VIA4-1, Upstate Biotechnolo-
gies; and 43DAG/8D5, Novocastra) and to neuroligin (4C12; Song et al.,
1999), with equal amounts of the total samples to allow precise compari-
sons. For domain analyses, 1 ml of brain extract containing 1 mM EGTA or
Figure 8. Developmental expression of  -dystroglycan. Dynamics 
of developmental expression of  -dystroglycan and neurexins. Brain 
homogenates from rats of the indicated ages were analyzed by SDS-
PAGE (50  g protein/lane) and immunoblotting with antibodies to 
the proteins shown. E17, embryonic day 17; P1–36, postnatal days 
1–36. Note the multiple bands observed for  -neurexins, including 
very large proteins ( 200 kD), which are due to the extensive alter-
native splicing of the  -neurexins. Asterisk identifies prominent pro-
teolytic breakdown product of synaptotagmin I.
Figure 9. Dystroglycan and  -latrotoxin compete for the same 
binding site in neurexins. Ig–N1 -1 was loaded with  -dystroglycan 
by incubation with an excess of total rat brain homogenate (lane 1) 
and extensive washing to remove nonbound proteins. Beads contain-
ing Ig–N1 -1 with bound dystroglycan were incubated with buffer 
containing the indicated amounts of  -latrotoxin and then centrifuged 
to separate unbound proteins in the supernatant (S) from bound pro-
teins in the pellet (P). Fractions were analysed by immunoblotting for 
 -dystroglycan (top) and  -latrotoxin (bottom). Note that  -latrotoxin 
quantitatively displaces bound  -dystroglycan. The slight difference in 
migration of  -dystroglycan on the SDS-gels between supernatant (S) 
and pellet (P) fractions may be due to differences in the buffer com-
position of the samples loaded or to preferential binding of a subset 
of glycosylated forms of dystroglycan by neurexin 1 .
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2 mM Ca
2  was incubated overnight with 30  l protein A–Sepharose con-
taining   8   g of the various Ig neurexin fusion proteins (Fig. 1). The
Sepharose beads were washed five times with 1 ml of the incubation buff-
ers, resuspended in 250  l of SDS-sample buffer, and 40  l were analyzed
by SDS-PAGE and Coomassie blue staining or immunoblotting. GST affin-
ity chromatography experiments were carried out with GST fusion proteins
immobilized on glutathione agarose (Sigma Aldrich) essentially as de-
scribed above for the Ig affinity chromatography procedures. To test if  -latro-
toxin can displace dystroglycan bound to neurexin, 10 ml brain extract
were incubated for 5 h at 4 C with 200  l of protein A–Sepharose contain-
ing 5  g of Ig–N1 -1 to saturate binding of dystroglycan to neurexin 1 .
After washing, the Sepharose beads were divided into nine tubes contain-
ing 0.1 ml buffer A with 0.5  g of BSA and 0.01–40 nM  -latrotoxin. After
overnight incubation, the supernatant was recovered by centrifugation
(800 g), the Sepharose was washed three times with 0.5 ml buffer A, resus-
pendend in 80  l sample buffer, and 10  l of the supernatant and the
bound material were analyzed by SDS-PAGE and immunoblotting.
Immunoprecipitations
Eight frozen rat brains were homogenized in 80 ml of 10 mM Hepes-
NaOH, pH 7.2, 0.32 M sucrose, and 1 mM CaCl2, centrifuged 10 min at
800 g to remove debris, and recentrifuged for 20 min at 14,000 g. The re-
sulting crude synaptosomes were resuspended for 30 min at 4 C in 40 ml
buffer B (20 mM Hepes-NaOH, pH 7.4, 0.1 M NaCl, 1% Triton X-100, 1
mM CaCl2, and 2.5 mM MgCl2) with protease inhibitors (0.1 g/liter PMSF,
10 mg/liter leupeptin, 10 mg/liter aprotinin, and 1 mg/liter pepstatin A). In-
soluble material was removed by centrifugation (30 min at 100,000 g), and
20 ml of the synaptosome extract were incubated overnight with 150  l of
a mixture of antibodies directed against the COOH terminus of all neurex-
ins (A473, B186, G393, G394) (Ushkaryov et al., 1992) or of the preim-
mune serum for B186, followed by 2 h incubation with 200  l of protein
A–Sepharose preequilibrated with buffer B. Afterwards, samples were cen-
trifuged (800 g for 2 min), the Sepharose beads were washed with 15 ml of
buffer B, and packed into a polypropylene column. The column was
washed with 5 and 4 ml buffer B, and eluted with 4 ml buffer B containing
1.0 M NaCl and 5 mM EDTA. The final wash and eluted materials were
TCA precipitated, resuspended in 160  l sample buffer, and 40  l were
analyzed by SDS-PAGE and immunoblotting using ECL detection.
Partial purification of dystroglycan
Brain, skeletal muscle, heart, and lung tissues from SVB/NJFVB mice were
disrupted with a polytron followed by Dounce homogenization in 50 mM
Tris-HCl, pH 7.4, 500 mM NaCl, 1% Triton X-100, 0.6  g/ml pepstatin A, 0.5
 g/ml leupeptin, 0.5  g/ml aprotinin, 0.75 mM benzamidine, 0.1 mM PMSF,
0.4  g/ml calpain inhibitor 1, and 0.4  g/ml calpeptin (buffer C). The homo-
genate was incubated for 2 h at 4 C, centrifuged at 140,000 g for 30 min at
4 C, and the supernatant was incubated with WGA agarose (Vector Laborato-
ries) overnight at 4 C. The WGA agarose was washed with buffer C contain-
ing 0.1% Triton X-100 and eluted with 50 mM Tris-HCl, pH 7.4, 0.1% Triton
X-100, and 0.3 M N-acetyl glucosamine. The eluate was concentrated with
Centricon-30 (Amicon). Extraction of dystroglycan from ES cells was per-
formed accordingly except that 50 mM Hepes, pH 7.4, 0.2 M NaCl, 1% NP-
40, and protease inhibitor mixture was used instead of buffer C.
Deglycosylation
For enzymatic deglycosylation, partially purified dystroglycan (30  l) was
boiled for 5 min in the presence of 0.7% SDS. 1% Triton X-100 was added,
and the pH was adjusted to 5.5 with 50 mM sodium-acetate. The prepara-
tion was incubated with 100 mU of sialidase and 2 mU of O-glycosidase
(Roche) at 37 C for 16 h, the pH was neutralized with 0.1 M sodium-phos-
phate buffer, and the mixture was incubated with 10 mU of N-glycosidase
F (Glyko) at 37 C for 16 h and boiled for 3 min. Control samples were
treated identically without enzymes. For chemical deglycosylation (Ervasti
and Campbell, 1993), dystroglycan (30  l) was lyophilized, resuspended
under nitrogen in 0.9 ml TFMS (Sigma-Aldrich) and 0.6 ml anisole (Sigma-
Aldrich), and incubated 5 h on ice. The reaction was quenched with 1.6 ml
ice-cold pyridin/H2O (3:5), dialyzed against cold distilled water, and ly-
ophilized. Control samples were treated identically without TFMS. Samples
were analyzed with the neurexin overlay assay or dystroglycan immuno-
blotting using mouse monoclonal antibody IIH6 and affinity purified rabbit
and goat polyclonal antibodies to  - and  -dystroglycan, respectively
(Ibraghimov-Beskrovnaya et al., 1992; Ervasti and Campbell, 1993).
Neurexin overlay assays
Proteins were separated by SDS-PAGE on 3–12% gradient gels and trans-
ferred to PVDF membranes. Membranes were blocked for 1 h in 5% dry
milk buffer D (10 mM triethanolamine, pH 7.6, 140 mM NaCl, 1 mM
CaCl2, 0.1% Tween 20), incubated overnight at room temperature in buffer
D containing 0.9 mg/liter Ig–N1 -1 in 5% BSA, and washed three times
with buffer D. Membranes were then incubated with HRP-conjugated pro-
tein A (Roche) for 1 h at room temperature and washed again three times
with buffer D.
Cell culture and immunofluorescence analysis
Dystroglycan heterozygous (DG
 / ) and homozygous mutant (DG
 / ) R1
ES cells were cultured (Henry and Campbell, 1998) on coverslips coated
with 5  g/cm
2 human fibronectin (Collaborative Biomedical Products). Af-
ter 24 h, the culture medium was replaced with medium containing 10
mM CaCl2 and 75 nM Ig–N1 -1 or Ig–control, incubated overnight,
washed with PBS, and fixed in 4% paraformaldehyde. Bound Ig fusion pro-
teins were detected by Texas red–conjugated anti–human (Fc domain) an-
tibody (Jackson ImmunoResearch Laboratories), and viewed by confocal
microscopy (Henry and Campbell, 1998; Henry et al., 2001).
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